MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. Read more about MC2 Therapeutics.
Our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions, including stability, tolerability, delivery to target tissue and convenience of use in daily routines. Read more about our platform.
MC2 therapeutics is converting skin biology into novel treatment paradigms for autoimmune and inflammatory skin conditions. Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fuelled by an entrepreneurial and creative mindset we aim to bring forward breakthrough discoveries and innovative technologies. Our drug candidates are powered by our proprietary formulation and drug delivery system PAD Technology™. Read more about our pipeline.